Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: A multi-center, real-world study.
Hepatol Res 2023. [PMID:
38153858 DOI:
10.1111/hepr.14007]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Revised: 12/12/2023] [Accepted: 12/23/2023] [Indexed: 12/30/2023]
Abstract
AIM
The study was conducted to evaluate the feasibility and safety profile of hepatic arterial infusion chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin (HAIC-FOLFOX) as an alternative therapeutic choice for patients with advanced hepatocellular carcinoma (HCC) that is refractory to systemic treatment including immune checkpoint blockades or molecular targeting agents.
METHODS
245 consecutive patients with advanced HCC who received HAIC-FOLFOX treatment after systemic treatment failure were retrospectively reviewed in six institutions and their survival, tumor response, and tolerance were assessed.
RESULTS
The median OS and PFS of the 209 included participants were 10.5 months (95%CI 8.1-12.9) and 6.0 months (95%CI 5.1-6.9), respectively. According to RECIST 1.1 criteria, the objective response rate was 21.1%, and the disease control rate was 64.6%. Multivariate analysis of risk factors of OS were ALBI grade (2 and 3 vs 1, HR = 1.57; 95%CI, 1.05-2.34; P = 0.028), tumor number (> 3 vs 1-3, HR = 2.18; 95% CI, 1.10-4.34; P = 0.026), extrahepatic spread (present vs absent, HR = 1.61, 95%CI, 1.06-2.45; P = 0.027), synchronous systemic treatment (present vs absent, HR = 0.55, 95%CI, 0.37-0.83; P = 0.004) and treatment response (responder vs nonresponder, HR = 0.30, 95%CI, 0.17-0.53; P < 0.001). Grade 3-4 AEs occurred in 59 (28.2%) HCC patients. All AEs were manageable, and deaths related to HAIC treatment were not observed.
CONCLUSIONS
Our findings support the effectiveness and safety of HAIC-FOLFOX treatment for patients with advanced HCC who have failed systemic treatment. This article is protected by copyright. All rights reserved.
Collapse